WilmerHale Advises PTC Therapeutics in Strategic Financing Collaboration with Blackstone

WilmerHale Advises PTC Therapeutics in Strategic Financing Collaboration with Blackstone

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
We guide clients through today’s ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Offering a sophisticated, full-service solution to private equity sponsors and entrepreneurs, from initial investment to exit.

On October 27, 2022, PTC Therapeutics, Inc., a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines for patients with rare disorders, announced that it has entered into a strategic financing collaboration with Blackstone for up to $1 billion in funding. The collaboration, which provides PTC with an initial $500 million commitment, will support PTC's mission to bring transformative medicines to patients by accelerating its pipeline and business development opportunities.

The WilmerHale team advising PTC Therapeutics was led by Brian Johnson and George Shuster and included Nathan Moore, Hilary Baker-Jennings, Jana Lama and Emily Powers.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel